King's College London

Research portal

From Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing Antibody-drug Conjugates (ADCs)

Research output: Contribution to journalArticlepeer-review

Standard

From Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing Antibody-drug Conjugates (ADCs). / Mantaj, Dr. Julia; Jackson, Dr. Paul J.M.; Rahman, Dr. Khondaker M. et al.

In: ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, Vol. 55, 12.2016, p. 2-29.

Research output: Contribution to journalArticlepeer-review

Harvard

Mantaj, DJ, Jackson, DPJM, Rahman, DKM & Thurston, PDE 2016, 'From Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing Antibody-drug Conjugates (ADCs)', ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, vol. 55, pp. 2-29. https://doi.org/10.1002/anie.201510610

APA

Mantaj, D. J., Jackson, D. P. J. M., Rahman, D. K. M., & Thurston, P. D. E. (2016). From Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing Antibody-drug Conjugates (ADCs). ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 55, 2-29. https://doi.org/10.1002/anie.201510610

Vancouver

Mantaj DJ, Jackson DPJM, Rahman DKM, Thurston PDE. From Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing Antibody-drug Conjugates (ADCs). ANGEWANDTE CHEMIE-INTERNATIONAL EDITION. 2016 Dec;55:2-29. https://doi.org/10.1002/anie.201510610

Author

Mantaj, Dr. Julia ; Jackson, Dr. Paul J.M. ; Rahman, Dr. Khondaker M. et al. / From Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing Antibody-drug Conjugates (ADCs). In: ANGEWANDTE CHEMIE-INTERNATIONAL EDITION. 2016 ; Vol. 55. pp. 2-29.

Bibtex Download

@article{b3e9ff4b90e54acdb08f39cb6e651bb4,
title = "From Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing Antibody-drug Conjugates (ADCs)",
abstract = "The pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) are a family of sequence-selective DNA minor-groove binding agents that form a covalent aminal bond between their C11-position and the C2-NH2 groups of guanine bases. The first example of a PBD monomer, the natural product anthramycin, was discovered in the 1960s, and the best known PBD dimer, SJG-136 (also known as SG2000, NSC 694501 or BN2629), was synthesized in the 1990s and has recently completed Phase II clinical trials in patients with leukaemia and ovarian cancer. More recently, PBD dimer analogues are being attached to tumor-targeting antibodies to create antibody–drug conjugates (ADCs), a number of which are now in clinical trials, with many others in pre-clinical development. This Review maps the development from anthramycin to the first PBD dimers, and then to PBD-containing ADCs, and explores both structure–activity relationships (SARs) and the biology of PBDs, and the strategies for their use as payloads for ADCs.",
author = "Mantaj, {Dr. Julia} and Jackson, {Dr. Paul J.M.} and Rahman, {Dr. Khondaker M.} and Thurston, {Prof. David E.}",
year = "2016",
month = dec,
doi = "10.1002/anie.201510610",
language = "English",
volume = "55",
pages = "2--29",
journal = "ANGEWANDTE CHEMIE-INTERNATIONAL EDITION",
issn = "1433-7851",
publisher = "WILEY-BLACKWELL",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - From Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing Antibody-drug Conjugates (ADCs)

AU - Mantaj, Dr. Julia

AU - Jackson, Dr. Paul J.M.

AU - Rahman, Dr. Khondaker M.

AU - Thurston, Prof. David E.

PY - 2016/12

Y1 - 2016/12

N2 - The pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) are a family of sequence-selective DNA minor-groove binding agents that form a covalent aminal bond between their C11-position and the C2-NH2 groups of guanine bases. The first example of a PBD monomer, the natural product anthramycin, was discovered in the 1960s, and the best known PBD dimer, SJG-136 (also known as SG2000, NSC 694501 or BN2629), was synthesized in the 1990s and has recently completed Phase II clinical trials in patients with leukaemia and ovarian cancer. More recently, PBD dimer analogues are being attached to tumor-targeting antibodies to create antibody–drug conjugates (ADCs), a number of which are now in clinical trials, with many others in pre-clinical development. This Review maps the development from anthramycin to the first PBD dimers, and then to PBD-containing ADCs, and explores both structure–activity relationships (SARs) and the biology of PBDs, and the strategies for their use as payloads for ADCs.

AB - The pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) are a family of sequence-selective DNA minor-groove binding agents that form a covalent aminal bond between their C11-position and the C2-NH2 groups of guanine bases. The first example of a PBD monomer, the natural product anthramycin, was discovered in the 1960s, and the best known PBD dimer, SJG-136 (also known as SG2000, NSC 694501 or BN2629), was synthesized in the 1990s and has recently completed Phase II clinical trials in patients with leukaemia and ovarian cancer. More recently, PBD dimer analogues are being attached to tumor-targeting antibodies to create antibody–drug conjugates (ADCs), a number of which are now in clinical trials, with many others in pre-clinical development. This Review maps the development from anthramycin to the first PBD dimers, and then to PBD-containing ADCs, and explores both structure–activity relationships (SARs) and the biology of PBDs, and the strategies for their use as payloads for ADCs.

U2 - 10.1002/anie.201510610

DO - 10.1002/anie.201510610

M3 - Article

VL - 55

SP - 2

EP - 29

JO - ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

JF - ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

SN - 1433-7851

ER -

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454